Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility
Fankhauser, C. D. Afferi, L. Stroup, S. P. Rocco, N. R. Olson, K. Bagrodia, A. Baky, F. Cazzaniga, W. Mayer, E. Nicol, D.
Fankhauser, C. D.
Afferi, L.
Stroup, S. P.
Rocco, N. R.
Olson, K.
Bagrodia, A.
Baky, F.
Cazzaniga, W.
Mayer, E.
Nicol, D.
Citations
Altmetric:
Abstract
Purpose To describe the perioperative safety, functional and immediate post-operative oncological outcomes of minimally invasive RPLND (miRPLND) for testis cancer. Methods We performed a retrospective multi-centre cohort study on testis cancer patients treated with miRPLND from 16 institutions in eight countries. We measured clinician-reported outcomes stratified by indication. We performed logistic regression to identify predictors for maintained postoperative ejaculatory function. Results Data for 457 men undergoing miRPLND were studied. miRPLND comprised laparoscopic (n = 56) or robotic (n = 401) miRPLND. Indications included pre-chemotherapy in 305 and post-chemotherapy in 152 men. The median retroperitoneal mass size was 32 mm and operative time 270 min. Intraoperative complications occurred in 20 (4%) and postoperative complications in 26 (6%). In multivariable regression, nerve sparing, and template resection improved ejaculatory function significantly (template vs bilateral resection [odds ratio (OR) 19.4, 95% confidence interval (CI) 6.5–75.6], nerve sparing vs non-nerve sparing [OR 5.9, 95% CI 2.3–16.1]). In 91 men treated with primary RPLND, nerve sparing and template resection, normal postoperative ejaculation was reported in 96%. During a median follow-up of 33 months, relapse was detected in 39 (9%) of which one with port site (< 1%), one with peritoneal recurrence and 10 (2%) with retroperitoneum recurrences. Conclusion The low proportion of complications or peritoneal recurrences and high proportion of men with normal postoperative ejaculatory function supports further miRPLND studies.
Authors
Fankhauser, C. D.
Afferi, L.
Stroup, S. P.
Rocco, N. R.
Olson, K.
Bagrodia, A.
Baky, F.
Cazzaniga, W.
Mayer, E.
Nicol, D.
Islamoglu, E.
de Vergie, S.
Saoud, R.
Eggener, S. E.
Nazzani, S.
Nicolai, N.
Hugar, L.
Sexton, W. J.
Matei, D. V.
De Cobelli, O.
Cheaib, J.
Pierorazio, P. M.
Porter, J.
Hermanns, T.
Hamilton, R. J.
Hiester, A.
Albers, P.
Clarke, N.
Mattei, A.
Afferi, L.
Stroup, S. P.
Rocco, N. R.
Olson, K.
Bagrodia, A.
Baky, F.
Cazzaniga, W.
Mayer, E.
Nicol, D.
Islamoglu, E.
de Vergie, S.
Saoud, R.
Eggener, S. E.
Nazzani, S.
Nicolai, N.
Hugar, L.
Sexton, W. J.
Matei, D. V.
De Cobelli, O.
Cheaib, J.
Pierorazio, P. M.
Porter, J.
Hermanns, T.
Hamilton, R. J.
Hiester, A.
Albers, P.
Clarke, N.
Mattei, A.
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Article
Citation
Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology. Springer Science and Business Media LLC; 2022.